New agents to prevent strokes in nonvalvular atrial fibrillation.

David Putney, Craig Pratt

Research output: Contribution to journalEditorialpeer-review


Anticoagulation for atrial fibrillation has been dependant on warfarin for the past 30 years. However, the recent FDA approvals of dabigatran and rivaroxaban and the expected approval for apixaban have provided several new alternatives for our patients. Many factors must be considered when selecting the most appropriate agent for preventing stroke in nonvalvular atrial fibrillation. The following trials have provided the foundation for decision making when considering alternatives to warfarin therapy.

Original languageEnglish (US)
Pages (from-to)44-46
Number of pages3
JournalMethodist DeBakey cardiovascular journal
Issue number3
StatePublished - 2012

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'New agents to prevent strokes in nonvalvular atrial fibrillation.'. Together they form a unique fingerprint.

Cite this